ClinicalTrials.gg
CompletedNCT01057433Updated Jun 22, 2021Results posted

Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin

A Phase 4 interventional study of Pitavastatin (NK-104) and Lopinavir/ritonavir in Healthy Volunteers, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-22.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.

Read the detailed description

This is a Phase 4, single center, open label, fixed-sequence, 2-way drug-drug interaction study.

Each subject will qualify for entry into the study not more than 30 days prior to admission into the clinical unit. Subjects will check into the clinical unit on Day -1 for baseline assessments. There will be one treatment period, with each subject receiving a once daily dose of pitavastatin 4 mg on Days 1 through 5 and Days 20 through 24 and a twice daily dose of lopinavir/ritonavir 400 mg/100 mg (two 200 mg/50 mg tablets per dose) on Days 9 through 24. Pitavastatin will be administered under fasting conditions in the morning and lopinavir/ritonavir will be administered under fasting conditions in the morning and evening.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

Kowa Research Institute, Inc. is the lead sponsor of 47 studies on the registry; 1 is open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 9 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult male or female volunteer aged 18 to 45 years, inclusive.
  • Subject has a of 18 to 30 kg/m2, inclusive.
  • Subject has normal hematology, serum chemistry, and urinalysis test results
  • Subject is able and willing to abstain from alcohol, grapefruit, caffeine, or caffeine containing products for 4 days before Day 1 until after completion of this study.
  • Subject is a nonsmoker or has quit smoking at least 6 months before the first dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Subject has had any surgery of the gastrointestinal tract likely to affect drug absorption, distribution, metabolism, or excretion.
  • Subject has had a previous allergy or intolerance to treatment with pitavastatin or lopinavir/ritonavir.
  • Subject has a history of drug or alcohol abuse.
  • Subject has had a illness within 4 weeks before the first dose of study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Pitavastatin

    Healthy adult subjects

    Drug: Pitavastatin (NK-104) · Drug: Lopinavir/ritonavir

Interventions

  • pitavastatin (NK-104) 4 mg once daily (QD)

    Also known as: Livalo

  • DrugLopinavir/ritonavir

    lopinavir/ritonavir 800 mg/200 mg

    Also known as: Kaletra

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to Tau (AUC 0-τ)

    Area under the curve from start to elimination.

    Time frame: 0, 1, 2, 3, 4, 5, 6, 8, and 12 hours after dosing on days 19 and 24

07

Results

Posted Aug 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneAll Subjects
Started24
Completed23
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryArea Under the Curve From Time 0 to Tau (AUC 0-τ)

Area under the curve from start to elimination.

Time frame:
0, 1, 2, 3, 4, 5, 6, 8, and 12 hours after dosing on days 19 and 24
Reported as:
Mean · ng•h/mL
Area Under the Curve From Time 0 to Tau (AUC 0-τ)
ng•h/mLAll Subjects
Area Under the Curve From Time 0 to Tau (AUC 0-τ)113.92 ± 53.80

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects—0/24 (0%)18/24 (75%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventAll Subjects
DiarrheaGastrointestinal disorders13/24
Abdominal painGastrointestinal disorders10/24
NauseaGastrointestinal disorders8/24
HeadacheNervous system disorders6/24
Anal hemorrhageGastrointestinal disorders4/24
FlatulenceGastrointestinal disorders4/24
DyspepsiaGastrointestinal disorders3/24
DysgeusiaNervous system disorders3/24
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/24
Dermatitis contactSkin and subcutaneous tissue disorders3/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Subjects
<=18 years0
Between 18 and 65 years24
>=65 years0
Age, Continuous
Age, Continuous(years)All Subjects
Mean33.8 ± 8.24
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female12
Male12
Region of Enrollment
Region of Enrollment(participants)All Subjects
United States24
08

Study locations

1 site
  • Austin, Texas, United States
09

References and documents

Publications

  • Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):158-64. doi: 10.1097/QAI.0b013e318251addb. PubMed 22627182 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2010
First posted
Jan 27, 2010
Start
Jan 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Aug 13, 2012
Last update
Jun 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01057433
Responsible party
Sponsor
First posted
Jan 27, 2010
Start date
Jan 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Aug 13, 2012
Last update
Jun 22, 2021

Study contacts

Roger Morgan, MD, FACS
study director · Kowa Research Institute, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion